Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
- Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures
- The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology
PARIS, France – March 18, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future.
